Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
MESO 
Mesoblast Ltd (MESO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/27/2025: MESO (3-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
3 Analysts rated it
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Year Target Price $27
Year Target Price $27
| 1 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Under performing |
| 0 | Sell |
Analysis of Past Performance
Type Stock | Historic Profit 528.71% | Avg. Invested days 41 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  5.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 06/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.39B USD | Price to earnings Ratio - | 1Y Target Price 27 |
Price to earnings Ratio - | 1Y Target Price 27 | ||
Volume (30-day avg) - | Beta 1.42 | 52 Weeks Range 5.78 - 22.00 | Updated Date 06/29/2025 |
52 Weeks Range 5.78 - 22.00 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.9 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -633.21% |
Management Effectiveness
Return on Assets (TTM) -4.85% | Return on Equity (TTM) -21.31% |
Valuation
Trailing PE - | Forward PE 454.55 | Enterprise Value 1460152750 | Price to Sales(TTM) 244.59 |
Enterprise Value 1460152750 | Price to Sales(TTM) 244.59 | ||
Enterprise Value to Revenue 137.12 | Enterprise Value to EBITDA -6.55 | Shares Outstanding 126998000 | Shares Floating 707670026 |
Shares Outstanding 126998000 | Shares Floating 707670026 | ||
Percent Insiders 0.06 | Percent Institutions 3.11 |
Analyst Ratings
Rating 4.33 | Target Price 27 | Buy 2 | Strong Buy 1 |
Buy 2 | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Mesoblast Ltd
Company Overview
History and Background
Mesoblast Ltd was founded in 2004 and is an Australian regenerative medicine company focused on developing allogeneic cellular medicines. It has navigated clinical trials, regulatory pathways, and partnerships to advance its pipeline.
Core Business Areas
- Cell-Based Therapies: Development and commercialization of allogeneic (off-the-shelf) cellular therapies for inflammatory diseases.
Leadership and Structure
The company is led by a board of directors and executive management team with expertise in biotechnology, clinical development, and commercialization. The structure is a typical biotech model with research, development, manufacturing, and commercial functions.
Top Products and Market Share
Key Offerings
- Remestemcel-L (RYONCIL): An allogeneic mesenchymal stem cell (MSC) therapy initially approved for steroid-refractory acute graft versus host disease (SR-aGVHD) in children. Limited market share due to narrow indication and high cost. Competitors include corticosteroids and other immunosuppressants.
Market Dynamics
Industry Overview
The regenerative medicine industry is rapidly evolving, with increasing investment and regulatory focus. It's characterized by high risk, high reward, and a long development timeline.
Positioning
Mesoblast is positioned as a leader in allogeneic cell therapy, with a focus on inflammatory diseases. Competitive advantages include a proprietary MSC platform and clinical data.
Total Addressable Market (TAM)
TAM for cell therapies is estimated in the billions of dollars, with significant growth potential. Mesoblast aims to capture a portion of this market through regulatory approvals and commercialization of its products.
Upturn SWOT Analysis
Strengths
- Proprietary MSC platform
- Clinical data in various inflammatory diseases
- Manufacturing capabilities
- Partnerships with leading institutions
Weaknesses
- High cash burn rate
- Regulatory hurdles
- Commercialization challenges
- Dependence on clinical trial success
Opportunities
- Expansion of indications for Remestemcel-L
- Development of new cell therapies
- Strategic partnerships
- Advancements in manufacturing technology
Threats
- Competition from other cell therapy companies
- Regulatory setbacks
- Clinical trial failures
- Economic downturn
Competitors and Market Share
Key Competitors
- Vertex Pharmaceuticals (VRTX)
- Novartis (NVS)
- Bristol Myers Squibb (BMY)
Competitive Landscape
Mesoblast faces intense competition from established pharmaceutical companies and emerging biotech firms. Its competitive advantage lies in its allogeneic MSC platform, but it needs to overcome commercialization challenges.
Growth Trajectory and Initiatives
Historical Growth: Mesoblast's growth has been driven by clinical trial progress and partnerships, but revenue has been limited due to regulatory approvals and commercialization delays.
Future Projections: Future growth depends on regulatory approvals, commercial launch, and partnership deals.
Recent Initiatives: Recent initiatives include focusing on expanding into new markets and developing new technologies.
Summary
Mesoblast is a regenerative medicine company with a promising MSC platform but faces significant regulatory and commercialization hurdles. While its technology holds potential, its financial stability and competitive landscape require careful consideration. The company needs to secure approvals and partnerships to achieve long-term success and growth. Investors should monitor clinical trial progress and regulatory decisions.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investing in biotechnology companies involves significant risks.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Mesoblast Ltd
Exchange NASDAQ | Headquaters Melbourne, VIC, Australia | ||
IPO Launch date 2015-11-13 | Founder, CEO, MD, Chairman of Scientific Advisory Board & Executive Director Dr. Silviu Itescu FACP, FACRA, FRACP, MBBS (Hons) | ||
Sector Healthcare | Industry Biotechnology | Full time employees 73 | Website https://www.mesoblast.com |
Full time employees 73 | Website https://www.mesoblast.com | ||
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease and biologic refractory inflammatory bowel disease, as well as Crohn's disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for the treatment or prevention of chronic heart failure and MPC-25-IC for the treatment or prevention of acute myocardial infarction; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa and for the treatment of neonatal hypoxic ischemic encephalopathy; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.